Contineum Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

-Contineum is focused on leading the Neuroscience, Inflammation and Immunology field-


-Successful completion of Initial Public Offering with strong syndicate of existing and new investors-

...

Related Keywords

San Diego ,California ,United States ,Carmine Stengone ,Third Development ,Contineum Therapeutics Inc ,Arcellx Inc ,Davidson College ,Johnson ,Nasdaq ,Development Expenses ,Drug Administration ,Revance Therapeutics Inc ,University Of North Carolina At Chapel Hill ,Contineum Therapeutics ,Chief Executive ,Recent Business ,Extended Cash Runway Through ,Initial Public ,Secondary Objectives ,Pipeline Through ,Third Development Candidate ,Investigational New Drug Application ,Myelin Gordon ,Myelin Gordon Conference ,Olivia Ware ,Revance Therapeutics ,North Carolina ,Cash Equivalents ,Johnson Innovative ,Financial Condition ,Months Ended March ,